1. Home
  2. DXCM vs EQR Comparison

DXCM vs EQR Comparison

Compare DXCM & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DXCM
  • EQR
  • Stock Information
  • Founded
  • DXCM 1999
  • EQR 1993
  • Country
  • DXCM United States
  • EQR United States
  • Employees
  • DXCM N/A
  • EQR N/A
  • Industry
  • DXCM Medical/Dental Instruments
  • EQR Real Estate Investment Trusts
  • Sector
  • DXCM Health Care
  • EQR Real Estate
  • Exchange
  • DXCM Nasdaq
  • EQR Nasdaq
  • Market Cap
  • DXCM 28.0B
  • EQR 27.9B
  • IPO Year
  • DXCM 2005
  • EQR 1993
  • Fundamental
  • Price
  • DXCM $80.91
  • EQR $74.03
  • Analyst Decision
  • DXCM Buy
  • EQR Buy
  • Analyst Count
  • DXCM 17
  • EQR 19
  • Target Price
  • DXCM $101.29
  • EQR $75.22
  • AVG Volume (30 Days)
  • DXCM 4.0M
  • EQR 1.5M
  • Earning Date
  • DXCM 10-24-2024
  • EQR 01-28-2025
  • Dividend Yield
  • DXCM N/A
  • EQR 3.62%
  • EPS Growth
  • DXCM 83.21
  • EQR 35.67
  • EPS
  • DXCM 1.67
  • EQR 2.44
  • Revenue
  • DXCM $3,954,000,000.00
  • EQR $2,940,829,000.00
  • Revenue This Year
  • DXCM $13.10
  • EQR N/A
  • Revenue Next Year
  • DXCM $14.79
  • EQR $4.01
  • P/E Ratio
  • DXCM $48.52
  • EQR $30.57
  • Revenue Growth
  • DXCM 16.19
  • EQR 3.33
  • 52 Week Low
  • DXCM $62.34
  • EQR $57.33
  • 52 Week High
  • DXCM $142.00
  • EQR $78.83
  • Technical
  • Relative Strength Index (RSI)
  • DXCM 70.00
  • EQR 47.50
  • Support Level
  • DXCM $77.50
  • EQR $73.38
  • Resistance Level
  • DXCM $79.38
  • EQR $78.32
  • Average True Range (ATR)
  • DXCM 2.64
  • EQR 1.20
  • MACD
  • DXCM 0.57
  • EQR 0.09
  • Stochastic Oscillator
  • DXCM 97.86
  • EQR 25.82

About DXCM DexCom Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

About EQR Equity Residential of Beneficial Interest

Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.

Share on Social Networks: